These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 19272155

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways.
    Hamy AS, Bonsang-Kitzis H, Lae M, Moarii M, Sadacca B, Pinheiro A, Galliot M, Abecassis J, Laurent C, Reyal F.
    PLoS One; 2016; 11(12):e0167397. PubMed ID: 28005906
    [Abstract] [Full Text] [Related]

  • 3. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Iwamoto T, Kelly C, Mizoo T, Nogami T, Motoki T, Shien T, Taira N, Hayashi N, Niikura N, Fujiwara T, Doihara H, Matsuoka J.
    Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
    [Abstract] [Full Text] [Related]

  • 4. Bioinformatic profiling of prognosis-related genes in the breast cancer immune microenvironment.
    Bai F, Jin Y, Zhang P, Chen H, Fu Y, Zhang M, Weng Z, Wu K.
    Aging (Albany NY); 2019 Nov 12; 11(21):9328-9347. PubMed ID: 31715586
    [Abstract] [Full Text] [Related]

  • 5. Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.
    Callari M, Cappelletti V, D'Aiuto F, Musella V, Lembo A, Petel F, Karn T, Iwamoto T, Provero P, Daidone MG, Gianni L, Bianchini G.
    Clin Cancer Res; 2016 Jan 15; 22(2):337-45. PubMed ID: 26423797
    [Abstract] [Full Text] [Related]

  • 6. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
    Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L.
    Cancer Res; 2010 Nov 01; 70(21):8852-62. PubMed ID: 20959472
    [Abstract] [Full Text] [Related]

  • 7. Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes.
    Hanker LC, Rody A, Holtrich U, Pusztai L, Ruckhaeberle E, Liedtke C, Ahr A, Heinrich TM, Sänger N, Becker S, Karn T.
    Breast Cancer Res Treat; 2013 Jan 01; 137(2):407-16. PubMed ID: 23242614
    [Abstract] [Full Text] [Related]

  • 8. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
    Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L.
    J Clin Oncol; 2010 Oct 01; 28(28):4316-23. PubMed ID: 20805453
    [Abstract] [Full Text] [Related]

  • 9. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
    Staaf J, Ringnér M, Vallon-Christersson J, Jönsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, Luts L, Grabau D, Fernö M, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A.
    J Clin Oncol; 2010 Apr 10; 28(11):1813-20. PubMed ID: 20231686
    [Abstract] [Full Text] [Related]

  • 10. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers.
    Tsang JY, Hui SW, Ni YB, Chan SK, Yamaguchi R, Kwong A, Law BK, Tse GM.
    Breast Cancer Res Treat; 2014 Jan 10; 143(1):1-9. PubMed ID: 24272079
    [Abstract] [Full Text] [Related]

  • 11. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
    Liu D, Zhou K.
    Clin Breast Cancer; 2020 Feb 10; 20(1):41-50.e8. PubMed ID: 31547956
    [Abstract] [Full Text] [Related]

  • 12. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.
    Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, Hoon DS.
    Breast Cancer Res; 2008 Feb 10; 10(3):R46. PubMed ID: 18485221
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration.
    Liu S, Foulkes WD, Leung S, Gao D, Lau S, Kos Z, Nielsen TO.
    Breast Cancer Res; 2014 Sep 06; 16(5):432. PubMed ID: 25193543
    [Abstract] [Full Text] [Related]

  • 14. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A, Malmström P, Bendahl PO, Elston CW, Falck AK, Forsare C, Grabau D, Rydén L, Stål O, Fernö M, South and South-East Swedish Breast Cancer Groups.
    Acta Oncol; 2017 Jan 06; 56(1):68-74. PubMed ID: 27762648
    [Abstract] [Full Text] [Related]

  • 15. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T, Hida AI, Inoue N, Imamura M, Fujimoto Y, Akazawa K, Hirota S, Miyoshi Y.
    Breast Cancer Res Treat; 2018 Feb 06; 168(1):135-145. PubMed ID: 29168063
    [Abstract] [Full Text] [Related]

  • 16. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M, Toyama T, Takahashi S, Sato S, Yoshimoto N, Endo Y, Asano T, Kobayashi S, Fujii Y, Yamashita H.
    Breast Cancer; 2015 May 06; 22(3):308-16. PubMed ID: 23771556
    [Abstract] [Full Text] [Related]

  • 17. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
    Fujimoto Y, Watanabe T, Hida AI, Higuchi T, Miyagawa Y, Ozawa H, Bun A, Fukui R, Sata A, Imamura M, Hirota S, Miyoshi Y.
    Breast Cancer; 2019 Nov 06; 26(6):738-747. PubMed ID: 31098866
    [Abstract] [Full Text] [Related]

  • 18. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
    Sinn BV, Weber KE, Schmitt WD, Fasching PA, Symmans WF, Blohmer JU, Karn T, Taube ET, Klauschen F, Marmé F, Schem C, Stickeler E, Ataseven B, Huober J, von Minckwitz G, Seliger B, Denkert C, Loibl S.
    Breast Cancer Res; 2019 Dec 11; 21(1):142. PubMed ID: 31829264
    [Abstract] [Full Text] [Related]

  • 19. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
    Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.
    Breast Cancer Res; 2009 Dec 11; 11(1):R11. PubMed ID: 19239686
    [Abstract] [Full Text] [Related]

  • 20. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A, Chalubinska J, Zawlik I, Szymanska B, Borowska-Garganisz E, Nowik M, Fendler W, Kubiak R, Pawlowska Z, Morawiec Z, Szemraj J.
    Neoplasma; 2012 Dec 11; 59(4):424-32. PubMed ID: 22489698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.